Etoposide

• BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part… Ended
  2024-515740-23-00 Phase III 11 countries Bristol-Myers Squibb Services Unlimited Company
• An interventional, open-label, Phase II study, to evaluate safety and efficacy of standard and high-dose chemotherapy associated with cranio… Ended
  2024-518964-11-01 Phase II 1 country Azienda Ospedaliera Universitaria Meyer IRCCS
• Study aimed at testing the activity of a course of chemo-immunotherapy with retifanlimab combined with platinum-etoposide followed by surger… Ended
  2024-516316-13-00 Phase II 1 country Fondazione GONO G.I.
• Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended
  2023-505989-29-00 Phase III 16 countries Amgen Inc.
• Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to expre… Ended
  2024-515467-66-00 Phase II 1 country Fundacio Sant Joan De Deu
• Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory… Ended
  2024-513295-18-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
• A multicentre phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maint… Ended
  2024-516157-41-00 Phase II 1 country G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
• Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended
  2023-503517-30-00 Phase III 14 countries Merck Sharp & Dohme LLC
• A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (… Ended
  2024-515902-15-00 Phase II 1 country Technische Universitaet Dresden
• AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas… Ended
  2024-517253-27-00 Phase III 1 country Medical University Of Silesia Katowice Poland
• A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in … Ended
  2024-513433-20-00 Phase II 1 country Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended
  2023-504959-27-00 Phase III 11 countries Merck Sharp & Dohme LLC
• Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended
  2023-504805-35-00 Phase I/II 10 countries Genmab A/S
• Reduced intensity radio-chemotherapy for stage IIA/B seminoma Ended
  2023-509663-24-00 Phase II 1 country Swiss Group for Clinical Cancer Research
• Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Ended
  2023-507062-34-00 Phase I (FiH) 5 countries Novartis Pharma AG
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell… Ended
  2023-503591-25-00 Phase III 12 countries Merck Sharp & Dohme LLC
• A trial to learn if different cancer treatment combinations are safe and work in people with advanced non-small cell lung cancer that has mu… Ended
  2023-504624-25-00 Phase II 5 countries AstraZeneca AB
• A phase II trial of MK-3475 (pembrolizumab) in children and young adults with classical Hodgkin lymphoma Ended
  2023-504821-38-00 Phase II 8 countries Merck Sharp & Dohme LLC
• Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours Ended
  2023-507582-25-00 Phase III 3 countries Rheinische Friedrich-Wilhelms-Universitaet Bonn
• EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study Ended
  2023-508478-27-00 Phase II 7 countries European Organisation For Research And Treatment Of Cancer
• A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatr… Ended
  2023-509834-20-00 Phase II 6 countries Novartis Pharma AG
• HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly d… Ended
  2022-501038-48-00 Phase II 2 countries Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended
  2023-509856-32-00 Phase III 5 countries Universitaetsklinikum Schleswig-Holstein
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended
  2024-515499-12-00 Phase III 12 countries Universita Degli Studi Di Milano Bicocca

Showing 73–96 of 114 trials